The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Prognostic Significance of Vascular Endothelial Growth Factor Protein in Node-Negative Breast Carcinoma
Abstract
BACKGROUND: The clinical outcome is generally positive for patients with node-negative breast carcinoma (i.e., those who do not have detectable metastases in the lymph nodes) who have been treated with surgery or surgery plus radiation therapy. In about 30% of the patients, however, the disease recurs, and they are at risk of death. Determination of valid new prognostic indicators would improve the ability to identify patients at high risk of recurrence. Breast cancer can entail substantial development of new blood vessels within the tumor tissue, and it is known that the growth and metastasis of solid tumors are dependent on such angiogenesis. The conversion of tumor cells to an angiogenic phenotype may be preceded by a change in the balance of angiogenic growth factors and angiogenesis inhibitors. PURPOSE: This study was conducted to determine if the levels of vascular endothelial growth factor (VEGF) protein, a potent endothelial growth factor and mediator of vascular permeability and angiogenesis, measured in the primary tumors of women with node-negative breast cancer are associated with known prognostic factors and patient survival. METHODS: By use of a selective enzymatic immunoassay, levels of VEGF protein were measured in cytosolic extracts of primary tumor tissue surgically obtained from 260 women with node-negative breast carcinoma who had been treated with surgery with or without radiation therapy but not with adjuvant therapy and who had been followed for a median time of 66 months. The relationships between VEGF concentrations and other prognostic dichotomous variables or clinical outcome were tested by the use of the Kolmogorov-Smirnov test and univariate and multivariate Cox analyses, respectively. The relationship between VEGF and hormone receptors (i.e., those for estrogen and progesterone) was examined by the use of Spearman's correlation analyses. All P values resulted from the use of two-sided statistical tests. RESULTS: Tumors from 247 (95%) of the 260 patients had detectable VEGF, ranging in concentration from 5.0 to 6523 pg/mg protein (median, 126.25 pg/mg protein). No statistically significant associations were found between VEGF and the other prognostic factors (e.g., age, menopausal status, histologic tumor type, tumor size, and hormone receptors) examined. Levels of VEGF were found to be prognostic for both relapse-free and overall survival in univariate and multivariate analyses (likelihood ratio tests; all four P values < .001). In the multivariate analysis, the first-order interaction term of VEGF and estrogen receptor was also prognostic for overall survival (likelihood ratio test; P = .05). CONCLUSIONS: The results show that cytosolic levels of VEGF in tumor tissue samples are indicative of prognosis for patients with node-negative breast carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050102 · Cited by 1,599
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,476
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,122
Martingale-based residuals for survival models
THERNEAU, T. M., GRAMBSCH, P. M., & FLEMING, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.1.147 · Cited by 1,099
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,098
Roberts, W. G., & Palade, G. E. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2369 · Cited by 1,033
Vascular permeability factor (VPF, VEGF) in tumor biology
Senger, D. R., Van De Water, L., Brown, L. F., Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M., & Dvorak, H. F. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665960 · Cited by 840
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Detmar, M., Brown, L. F., Claffey, K. P., Yeo, K. T., Kocher, O., Jackman, R. W., Berse, B., & Dvorak, H. F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1141 · Cited by 685
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., & Senger, D. R. (1993) · PubMed · Cited by 564
Fava, R. A., Olsen, N. J., Spencer-Green, G., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Senger, D. R., Dvorak, H. F., & Brown, L. F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.341 · Cited by 520
Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.356 · Cited by 464
Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., & Pozza, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.454 · Cited by 464
Self-citationGoto, F., Goto, K., Weindel, K., & Folkman, J. (1993) · PubMed · Cited by 459
Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian Carcinoma
Boocock, C. A., Charnock-Jones, D. S., Sharkey, A. M., McLaren, J., Barker, P. J., Wright, K. A., Twentyman, P. R., & Smith, S. K. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.7.506 · Cited by 456
Toi, M., Hoshina, S., Takayanagi, T., & Tominaga, T. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02904.x · Cited by 391
Self-citationVascular endothelial growth factor
Ferrara, N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00387-5 · Cited by 355
Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression.
Brogi, E., Schatteman, G., Wu, T., Kim, E. A., Varticovski, L., Keyt, B., & Isner, J. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118437 · Cited by 342
Delivery of Molecular Medicine to Solid Tumors
Jain, R. K. (1996) · Science · doi:10.1126/science.271.5252.1079 · Cited by 312
Koolwijk, P., van Erck, M. G., de Vree, W. J., Vermeer, M. A., Weich, H. A., Hanemaaijer, R., & van Hinsbergh, V. W. (1996) · The Journal of cell biology · doi:10.1083/jcb.132.6.1177 · Cited by 296
Zhang, H.-T., Craft, P., Scott, P. A. E., Ziche, M., Weich, H. A., Harris, A. L., & Bicknell, R. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.3.213 · Cited by 265
Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., et al. (1996) · PubMed · Cited by 244
Self-citationAngiogenesis and breast cancer metastasis
Ellis, L., & Fidler, I. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92774-3 · Cited by 232
Viglietto, G., Maglione, D., Rambaldi, A., Cerutti, J. M., Romano, A., Trapasso, F., Fedele, M., Ippolito, P., Chiappetta, G., & Botti, G. (1995) · PubMed · Cited by 208
Rak, J., Filmus, J., & Kerbel, R. S. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00396-6 · Cited by 202
Quantitative analysis of vascular endothelial growth factor in primary breast cancer
Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T., & Tominaga, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960315)77:6<1101::aid-cncr15>3.0.co;2-5 · Cited by 193
Self-citationRamakrishnan, S., Olson, T. A., Bautch, V. L., & Mohanraj, D. (1996) · PubMed · Cited by 139
Toi, M., Inada, K., Hoshina, S., Suzuki, H., Kondo, S., & Tominaga, T. (1995) · PubMed · Cited by 121
Self-citationObermair, A., Kurz, C., Czerwenka, K. F., Thoma, M., Kaider, A., Wagner, T. M., Gitsch, G., & Sevelda, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620203 · Cited by 89
Pötgens, A. J. G., van Altena, M. C., Lubsen, N. H., Ruiter, D. J., & de Waal, R. M. W. (1996) · Europe PMC (PubMed Central) · Cited by 64
Cited by
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Metadata
- Authors
- Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., Hanatani, M., Matsubara, I., & Suzuki, H.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-01-15
- Volume
- 89
- Issue
- 2
- Pages
- 139-147
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2013965516
- Cited by
- 494
- References
- 47
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.